Back to Search Start Over

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

Authors :
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service d'urologie
Gillessen, Silke
Armstrong, Andrew
Attard, Gert
Beer, Tomasz M
Beltran, Himisha
Bjartell, Anders
Bossi, Alberto
Briganti, Alberto
Bristow, Robert G
Bulbul, Muhammad
Caffo, Orazio
Chi, Kim N
Clarke, Caroline S
Clarke, Noel
Davis, Ian D
de Bono, Johann S
Duran, Ignacio
Eeles, Ros
Efstathiou, Eleni
Efstathiou, Jason
Ekeke, Onyeanunam Ngozi
Evans, Christopher P
Fanti, Stefano
Feng, Felix Y
Fizazi, Karim
Frydenberg, Mark
George, Dan
Gleave, Martin
Halabi, Susan
Heinrich, Daniel
Higano, Celesta
Hofman, Michael S
Hussain, Maha
James, Nick
Jones, Robert
Kanesvaran, Ravindran
Khauli, Raja B
Klotz, Laurence
Leibowitz, Raya
Logothetis, Chris
Maluf, Fernando
Millman, Robin
Morgans, Alicia K
Morris, Michael J
Mottet, Nicolas
Mrabti, Hind
Murphy, Declan G
Murthy, Vedang
Oh, William K
Ost, Piet
O'Sullivan, Joe M
Padhani, Anwar R
Parker, Chris
Poon, Darren M C
Pritchard, Colin C
Rabah, Danny M
Rathkopf, Dana
Reiter, Rob E
Rubin, Mark
Ryan, Charles J
Saad, Fred
Sade, Juan P
Sartor, Oliver
Scher, Howard I
Shore, Neal
Skoneczna, Iwona
Small, Eric
Smith, Matthew
Soule, Howard
Spratt, Daniel E
Sternberg, Cora N
Suzuki, Hiroyoshi
Sweeney, Christopher
Sydes, Matthew R
Taplin, Mary-Ellen
Tilki, Derya
Tombal, Bertrand
Türkeri, Levent
Uemura, Hiroji
Uemura, Hirotsugu
van Oort, Inge
Yamoah, Kosj
Ye, Dingwei
Zapatero, Almudena
Omlin, Aurelius
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service d'urologie
Gillessen, Silke
Armstrong, Andrew
Attard, Gert
Beer, Tomasz M
Beltran, Himisha
Bjartell, Anders
Bossi, Alberto
Briganti, Alberto
Bristow, Robert G
Bulbul, Muhammad
Caffo, Orazio
Chi, Kim N
Clarke, Caroline S
Clarke, Noel
Davis, Ian D
de Bono, Johann S
Duran, Ignacio
Eeles, Ros
Efstathiou, Eleni
Efstathiou, Jason
Ekeke, Onyeanunam Ngozi
Evans, Christopher P
Fanti, Stefano
Feng, Felix Y
Fizazi, Karim
Frydenberg, Mark
George, Dan
Gleave, Martin
Halabi, Susan
Heinrich, Daniel
Higano, Celesta
Hofman, Michael S
Hussain, Maha
James, Nick
Jones, Robert
Kanesvaran, Ravindran
Khauli, Raja B
Klotz, Laurence
Leibowitz, Raya
Logothetis, Chris
Maluf, Fernando
Millman, Robin
Morgans, Alicia K
Morris, Michael J
Mottet, Nicolas
Mrabti, Hind
Murphy, Declan G
Murthy, Vedang
Oh, William K
Ost, Piet
O'Sullivan, Joe M
Padhani, Anwar R
Parker, Chris
Poon, Darren M C
Pritchard, Colin C
Rabah, Danny M
Rathkopf, Dana
Reiter, Rob E
Rubin, Mark
Ryan, Charles J
Saad, Fred
Sade, Juan P
Sartor, Oliver
Scher, Howard I
Shore, Neal
Skoneczna, Iwona
Small, Eric
Smith, Matthew
Soule, Howard
Spratt, Daniel E
Sternberg, Cora N
Suzuki, Hiroyoshi
Sweeney, Christopher
Sydes, Matthew R
Taplin, Mary-Ellen
Tilki, Derya
Tombal, Bertrand
Türkeri, Levent
Uemura, Hiroji
Uemura, Hirotsugu
van Oort, Inge
Yamoah, Kosj
Ye, Dingwei
Zapatero, Almudena
Omlin, Aurelius
Source :
European Urology, Vol. 82, no. 1, p. 115-141 (2022)
Publication Year :
2022

Abstract

Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. To present the voting results from APCCC 2021. The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identi

Details

Database :
OAIster
Journal :
European Urology, Vol. 82, no. 1, p. 115-141 (2022)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1328223643
Document Type :
Electronic Resource